AP NEWS

Global Orphan and Rare Dermatology Drugs Market to 2024 - An Increasingly Competitive Landscape as New Companies Enter the Market with Novel Products, Driving Strong Market Growth - ResearchAndMarkets.com

October 8, 2018

DUBLIN--(BUSINESS WIRE)--Oct 8, 2018--The “Global Orphan and Rare Dermatology Drugs Market to 2024 - An Increasingly Competitive Landscape as New Companies Enter the Market with Novel Products, Driving Strong Market Growth” report has been added to ResearchAndMarkets.com’s offering.

The premium product market size for orphan and rare dermatology therapeutics was valued at $1.64 billion in 2017 and it is expected to grow at a compound annual growth rate (CAGR) of 20.5% to $6.07 billion in 2024.

Dermatology is a highly diverse therapy area, in terms of severity and clinical presentation, which deals with diseases of the skin, hair and nails. Whilst an orphan disease is a disease that is neglected in terms of research and funding and in the US, a disease is considered to be rare if it affects fewer than 200,000 people.

Many orphan and rare dermatology disorders are associated with significant quality of life impairments, particularly if the disease is insufficiently controlled. In particular, disease visibility can have a profoundly negative impact on patient confidence. However, the current therapeutics market is a highly genericized therapy area and there exists a significant unmet need for more efficacious and safer treatment options that treat the underlying causes of disease as opposed to managing the symptoms.

This report covers all orphan and rare dermatology disorders, but there is a particular focus on six key diseases, systemic sclerosis (scleroderma), alopecia, epidermolysis bullosa, pemphigus vulgaris, vitiligo and cutaneous lupus erythematosus, as these conditions have the largest pipelines within the therapy area.

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Key Marketed Products

4 Pipeline Landscape Assessment

5 Multi-scenario Market Forecast to 2024

6 Company Analysis and Positioning

7 Strategic Consolidations

8 Appendix

Companies Mentioned

AbbVie Novartis Swedish Orphan Biovitrum Regeneron Pharmaceuticals Johnson & Johnson Celgene Pfizer Merck & Co. Horizon Pharma

For more information about this report visit https://www.researchandmarkets.com/research/j9m9n8/global_orphan_and?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181008005283/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Dermatological Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/08/2018 04:46 AM/DISC: 10/08/2018 04:46 AM

http://www.businesswire.com/news/home/20181008005283/en

AP RADIO
Update hourly